The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

Blood. 2012 Dec 13;120(25):5084-5. doi: 10.1182/blood-2012-09-453555.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use*
  • Azacitidine / therapeutic use*
  • Blood Cell Count
  • Cytogenetic Analysis
  • Follow-Up Studies
  • Humans
  • Myelodysplastic Syndromes / diagnosis*
  • Myelodysplastic Syndromes / drug therapy*
  • Prognosis
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic
  • Azacitidine